FOLIKA-PROBIOTIC- lactobacillus acidophilus, bifidobacterium lactis bi-07 capsule United States - English - NLM (National Library of Medicine)

folika-probiotic- lactobacillus acidophilus, bifidobacterium lactis bi-07 capsule

innovida phamaceutique corporation - lactobacillus acidophilus (unii: 1prr1v42v5) (lactobacillus acidophilus - unii:1prr1v42v5), bifidobacterium lactis bi-07 (unii: w5mjx9c73y) (bifidobacterium lactis bi-07 - unii:w5mjx9c73y) -

YOSPRALA- aspirin and omeprazole tablet, film coated United States - English - NLM (National Library of Medicine)

yosprala- aspirin and omeprazole tablet, film coated

innovida phamaceutique corporation - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - yosprala, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. the aspirin component of yosprala is indicated for: - reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, - reducing the combined risk of death and nonfatal mi in patients with a previous mi or unstable angina pectoris, - reducing the combined risk of mi and sudden death in patients with chronic stable angina pectoris, - use in patients who have undergone revascularization procedures (coronary artery bypass graft [cabg] or percutaneous transluminal coronary angioplasty [ptca]) when there is a pre-existing condition for which aspirin is already indicated. the omeprazole component of yosprala is indicated for decreasing the risk of developing aspirin-associated gastric u

ASPIRIN AND OMEPRAZOLE DELAYED-RELEASE TAB- aspirin and omeprazole tablet, film coated United States - English - NLM (National Library of Medicine)

aspirin and omeprazole delayed-release tab- aspirin and omeprazole tablet, film coated

innovida phamaceutique corporation - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - aspirin and omeprazole delayed-release tablets, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. the aspirin component of aspirin and omeprazole delayed-release tablets is indicated for: - reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, - reducing the combined risk of death and nonfatal mi in patients with a previous mi or unstable angina pectoris, - reducing the combined risk of mi and sudden death in patients with chronic stable angina pectoris, - use in patients who have undergone revascularization procedures (coronary artery bypass graft [cabg] or percutaneous transluminal coronary angioplasty [ptca]) when there is a pre-existing condition for which aspirin is already indicated. the omeprazole component of aspirin and

SUMATRIPTAN AND NAPROXEN SODIUM tablet, film coated United States - English - NLM (National Library of Medicine)

sumatriptan and naproxen sodium tablet, film coated

innovida phamaceutique corporation - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo), naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - sumatriptan and naproxen sodium tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. limitations of use: - use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan and naproxen sodium tablets, reconsider the diagnosis of migraine before sumatriptan and naproxen sodium tablets are administered to treat any subsequent attacks. - sumatriptan and naproxen sodium tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of sumatriptan and naproxen sodium tablets have not been established for cluster headache. sumatriptan and naproxen sodium tablets are contraindicated in the following patients: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and preca

FOLIKA-V- ascorbic acid, cholecalciferol, thiamine, vitamin b6. folate, vitamin b12, nahd, coenzyme q10 tablet United States - English - NLM (National Library of Medicine)

folika-v- ascorbic acid, cholecalciferol, thiamine, vitamin b6. folate, vitamin b12, nahd, coenzyme q10 tablet

innovida phamaceutique corporation - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w), nadh (unii: 4j24dq0916) (nadh - unii:4j24dq0916), ubidecarenone (unii: ej27x76m46) (ubidecarenone - unii:ej27x76m4 -

FOLIKA-MG- beta carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, pyridoxine hydrochloride, folic acid, United States - English - NLM (National Library of Medicine)

folika-mg- beta carotene, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, dl-, pyridoxine hydrochloride, folic acid,

innovida phamaceutique corporation - beta carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cobalamin (unii: 8406ey2oqa) (cobalamin - unii:8406ey2oqa), b -

FOLIKA-NC- ascorbic acid, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, cobalamin, biotin, pantothenic acid, foli United States - English - NLM (National Library of Medicine)

folika-nc- ascorbic acid, thiamine, riboflavin, niacinamide, pyridoxine hydrochloride, cobalamin, biotin, pantothenic acid, foli

innovida phamaceutique corporation - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cobalamin (unii: 8406ey2oqa) (cobalamin - unii:8406ey2oqa), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), pantothenic acid (unii: 19f5hk2737) (pantothenic acid - un -

FOLIKA-CI- ascorbic acid, cholecalciferol, thiamine, pyridoxal, folic acid, cobalamin, calcium carbonate, ferrous bisglycinate, United States - English - NLM (National Library of Medicine)

folika-ci- ascorbic acid, cholecalciferol, thiamine, pyridoxal, folic acid, cobalamin, calcium carbonate, ferrous bisglycinate,

innovida phamaceutique corporation - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), pyridoxal 5-phosphate glutamate (unii: up2u9o910m) (pyridoxal - unii:3thm379k8a), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cobalamin (unii: 8406ey2oqa) (cobalamin - unii:8406ey2oqa), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), ferrous bisglycinate (unii -

FOLIKA-D- folic acid, cholecalciferol, folate tablet United States - English - NLM (National Library of Medicine)

folika-d- folic acid, cholecalciferol, folate tablet

innovida phamaceutique corporation - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - folic acid 1.67 mg

FOLIKA-T- vitamin c, thiamine, riboflavin, niacin, vitamin b6, folate, vitamin b12, biotin, panothenic acid tablet United States - English - NLM (National Library of Medicine)

folika-t- vitamin c, thiamine, riboflavin, niacin, vitamin b6, folate, vitamin b12, biotin, panothenic acid tablet

innovida phamaceutique corporation - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), pa -